Related Suggestion
(Dongguan, China, 04 February 2020) 2020 has an unusual start-up to the world's biotechnology organizations giving the new coronavirus outbreak. And as a global IVD reagent raw material supplier, Fapon acts promptly to fight against the novel coronavirus by providing pivotal raw materials to the downstream diagnostic companies and taking proactive measures to ensure the safety of Fapon employees, especially for individuals who travel to infected regions during the Chinese New Year holiday. To date, no suspected or confirmed case of the virus has been found among Fapon employees.
Followed through the measures of disease prevention and controls arranged by the Chinese Health Department and the Dubai International Aiport, Fapon International Sales Team had arrived Dubai smoothly and exhibits at the Dubai International Convention & Exhibition Centre for Medlab Middle East. Besides the demonstration of new IVD products to visitors, hygiene measures are also implemented at Fapon’s booth ZA.A40 from 3 to 6 February by wearing medical masks and offering alcohol-based hand sanitizer to visitors.
Unsurprisingly, the situation of the coronavirus outbreak in China provokes different questions from the onsite visitors alongside the discussion of Fapon’s new IVD products. “We appreciate our customers’ concerns and the confidence they give to our government and healthcare communities in China for trusting our work to monitor the virus outbreak.”
As the Fapon Sales Team continued explains, “Right after the outbreak, we formed an emergency response team covering functions from R&D, Production, QC, Sales, Marketing, Logistics, etc. We hoped to give the most proactive support to reagent manufacturers, by offering 1 million free doses of the novel coronavirus reagent raw materials, they are able to launch effective reagent and distribute to end users timely.”
Fapon’s explanation and actions to the coronavirus are indeed a testament to the company‘s core competency of IVD product research, development and manufacturing. Extensive conversations are unfolded to explore business opportunities through the learning of coronavirus outbreak and the recommended products presented by Fapon.
The demonstration of POCT and CLIA Solutions gain great attention from the booth visitors. Numerous appointed customers visit to discover the new 120T/H CLIA analyzer and the updated information of the POCT test panel as it is expected to expand to 36 parameters in 2020.
The Immunoturbidimetric Reagent Development Solution that gains favorable reputations from partners in the Middle East and Europe is highlighted owning to its flexible cooperation models and exceptional technology. The performances of the flagship parameters such as HbA1c, CRP and ASO are shared with customers.
The IVD Reagent Raw Materials for Rapid Test, ELISA and CLIA to tackle the burden of infectious, tropical and cardiac disease in the Middle East are also underlined, featured parameters include HIV, HCV, HBV, TP, Flu A/B, MA, Dengue-NS1, cTnI, cTnT, NT-proBNP, etc.
Congratulation on Fapon‘s initial showcase in 2020 at Medlab ME. Deep gratitude to all guests who visited Fapon at the Medlab Middle East and expressed their supports to the situation in China. As the healthcare reform in the Middle East is continuously marching, Fapon is committed to providing high-quality IVD products to assist the growth of the market share of all Fapon business partners.
